Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
Pulse Biosciences, Inc. reports that its Board of Directors has approved resolutions allowing TD Securities (USA) LLC, as sales agent under an existing Equity Distribution Agreement, to sell common stock to one or more company affiliates at the then current market trading price without a discount.
The Equity Distribution Agreement, dated February 19, 2026, permits at-the-market offerings of common stock with an aggregate offering price of up to $59,976,196. The company notes that Co-Chairman and major stockholder Robert Duggan, who beneficially owned approximately 72% of outstanding common stock as of March 31, 2026, and Chief Executive Officer and Co-Chairman Paul LaViolette have indicated they are likely to purchase shares in the near term, but without any binding commitments or specified amounts.
Pulse Biosciences reported first quarter 2026 results and clinical trial updates. For the three months ended March 31, 2026, revenue was $0.4 million and GAAP net loss was $18.6 million, compared to a net loss of $16.8 million a year earlier, as spending on clinical programs increased.
Total GAAP costs and expenses were $19.6 million, with research and development of $12.6 million and selling, general and administrative expenses of $6.6 million. Non-GAAP costs and expenses were $17.4 million and non-GAAP net loss was $16.4 million.
Cash and cash equivalents were $68.3 million as of March 31, 2026, with $14.6 million used in operating activities during the quarter. The company highlighted accelerated enrollment for its NANOPULSE-AF pivotal trial, now targeting completion in early Q4 2026, and plans to complete NANOCLAMP-AF enrollment by the end of the first half of 2027.
Pulse Biosciences filed an amended annual report mainly to add Part III information on directors, executive compensation, ownership, and governance, without updating financial results. The filing details a seven-member board, its committees, independence determinations, and a Strategic Advisory Committee focused on business strategy.
New CEO Paul A. LaViolette received 2025 total compensation of about $7.4 million, largely from performance- and market-based stock options with significant upside, while CFO Jon Skinner received about $2.8 million including a large start-date option. The compensation committee paid 2024 bonuses at 88.88% of target but granted no 2025 cash bonuses after determining 2025 corporate objectives were not achieved.
Ownership is highly concentrated: director Robert W. Duggan beneficially owns about 71.6% of common stock, and all directors and executive officers as a group hold about 74.7%. The company also outlines sizable option holdings for directors and executives and provides updated share reserves across its equity, ESPP, and inducement plans.
Pulse Biosciences, Inc. furnished an update on its first-in-human clinical study of the nPulse Cardiac Catheter System for atrial fibrillation, highlighting sustained procedure success and efficiency metrics from a multicenter feasibility study in Europe.
At Heart Rhythm 2026, investigators reported 100% procedural success at 6 months in 95 evaluable patients and 96% procedural success at one year in 51 evaluable patients, with a 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year. Among 177 treated patients, serious adverse events related to the primary safety endpoint occurred in 1.7% of subjects. The company also posted an updated investor presentation and a detailed press release with these results.
Pulse Biosciences, Inc. furnished an updated investor presentation on its website, highlighting progress and plans across its cardiac and soft tissue programs. The deck adds new details on the pivotal clinical study of its nsPFA Cardiac Catheter for treating atrial fibrillation, describes the next-generation nPulse cardiac catheter under development, and outlines 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation. The company may use this presentation in meetings with investors and analysts. The investor deck is provided as an exhibit and is treated as furnished, not filed, under securities laws, and includes forward-looking statements subject to risks and uncertainties.
Pulse Biosciences, Inc. appointed Liane R. Teplitsky as Chief Operating Officer effective April 8, 2026, and expanded Dr. David Kenigsberg’s role as full-time Chief Medical Officer to support development of its nPulse cardiac catheter ablation system.
Ms. Teplitsky’s at-will Employment Agreement provides a $525,000 annual base salary and a target bonus equal to 70% of base salary, plus eligibility for standard executive benefits. She received a nonstatutory stock option to purchase 700,000 shares at $19.06 per share and 200,000 performance-based restricted stock units under the 2017 Inducement Equity Incentive Plan, with time-based and performance-based vesting tied to market capitalization and revenue milestones.
Pulse also granted inducement options covering 7,700 shares to two other new employees, each with a $19.06 exercise price and four-year time-based vesting.
Pulse Biosciences reported that it has enrolled and treated the first seven patients in its NANOPULSE-AF IDE pivotal clinical study of the nPulse™ Cardiac Catheter System for recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The prospective, multicenter investigation plans to enroll about 215 participants across multiple sites in the United States and Europe.
Primary endpoints will be assessed at 6 and 12 months post-ablation to evaluate procedural success and safety. The study builds on a first-in-human feasibility trial that showed 96% procedural success at 12 months and 100% acute success, in a setting where atrial fibrillation recurrence of 20–25% is described as typical. The system uses nanosecond pulsed field ablation energy and is integrated with Abbott’s EnSite X 3D electroanatomical mapping software.
UECKER DARRIN reported acquisition or exercise transactions in this Form 4 filing.
PULSE BIOSCIENCES, INC. reported that Chief Technology Officer Darrin Uecker received a grant of 100,000 Restricted Stock Units. Each RSU represents a contingent right to receive one share of common stock. Following this grant, he holds 100,000 RSUs.
The RSUs are scheduled to fully vest on March 23, 2029, the three-year anniversary of the grant, provided he continues to serve with the company through that date. This is a stock-based compensation award rather than an open-market share purchase or sale.
Pulse Biosciences, Inc. reported that its Compensation Committee granted Chief Technology Officer Darrin R. Uecker a restricted stock unit award covering 100,000 shares of common stock. The award recognizes his continued leadership of the company’s product development efforts for the treatment of atrial fibrillation.
The RSUs vest in full on the third anniversary of the grant date, subject to the terms of the grant agreement and the company’s Amended and Restated 2017 Equity Incentive Plan. This is an equity-based compensation grant designed to align the CTO’s incentives with long-term company performance.
Pulse Biosciences filed an 8-K describing a strategic and organizational realignment to prioritize development and future commercialization of its nPulse Cardiac Catheter Ablation System for treating atrial fibrillation. The company is reallocating capital and resources toward its electrophysiology program after reporting strong feasibility data.
In the near term, the realignment includes reducing headcount in sales and marketing while actively hiring in product development roles. The move follows European feasibility results in over 150 patients that the company describes as demonstrating speed, safety, and durable efficacy, with additional 12‑month follow-up data to be presented at Heart Rhythm 2026.